Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07548450 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Mosunetuzumab in Combination With Pirtobrutinib in Patients With Relapsed or Refractory Waldenstrom Macroglobulinemia (MPOWER)

Study acronym: MPOWER
StatusNot Yet Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 4 months later Jun 2034 → Nov 2034
See other at-risk trials from University of Utah

Record History

  1. Start date: Jun 2026 to Nov 2026 Primary completion pushed from Jun 2034 to Nov 2034 · Completion pushed from Jun 2035 to Nov 2035 · Eligibility criteria expanded, about 103 words · 1 more Show 4 more changesShow less
    • Primary completion pushed from Jun 2034 to Nov 2034
    • Completion pushed from Jun 2035 to Nov 2035
    • Eligibility criteria expanded, about 103 words
    • Secondary endpoints: details revised at 1 of 5 entries
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this clinical trial it to test the safety and tolerability of the study drugs mosunetuzumab in combination with pirtobrutinib in patients with relapsed or refractory Waldenstrom's Macroglobulinemia.
Trial Details
NCT Number NCT07548450
Lead Sponsor University of Utah
Collaborators: Genentech, Inc., Eli Lilly and Company
Conditions Waldenstrom Macroglobulinemia
Enrollment 25 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov